-
EP3849527
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3849527
| EP3849527 - FORMULATIONS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 18.06.2021 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 21.03.2020 | Most recent event Tooltip | 27.09.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Syneurx International (Taiwan) Corp. 20F-10, No. 99 Sec. 1, Xintai 5th Rd. Xizhi District New Taipei City 221 / TW | [2021/29] | Inventor(s) | 01 /
TSAI, Guochuan Emil 1380 South Marengo Avenue Pasadena, CA 91106 / US | 02 /
WANG, Ching-Cheng 20F-10, No. 99, Sec. 1 Xintai 5th Rd. Xizhi District New Taipei City, Taiwan 221 / CN | 03 /
YANG, Hsin-Hsin 20F-10, No. 99, Sec. 1 Xintai 5th Rd. Xizhi District New New Taipei City, Taiwan 221 / CN | 04 /
TSAI, Hsuan-Ang 20F-10, No. 99, Sec. 1 Xintai 5th Rd. Xizhi District New New Taipei City, Taiwan 221 / CN | [2021/29] | Representative(s) | Cabinet Becker et Associés 25, rue Louis le Grand 75002 Paris / FR | [2021/29] | Application number, filing date | 19860429.0 | 12.09.2019 | [2021/29] | WO2019CN105635 | Priority number, date | US201816130747 | 13.09.2018 Original published format: US201816130747 | [2021/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020052643 | Date: | 19.03.2020 | Language: | EN | [2020/12] | Type: | A1 Application with search report | No.: | EP3849527 | Date: | 21.07.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.03.2020 takes the place of the publication of the European patent application. | [2021/29] | Search report(s) | International search report - published on: | CN | 19.03.2020 | (Supplementary) European search report - dispatched on: | EP | 10.06.2022 | Classification | IPC: | A61K9/28, A61K31/42, A61K9/00, A61K9/48, A61K9/70, A61P25/16, A61P25/18, A61P25/22, A61P25/24, A61P25/28, A61P31/06 | [2022/28] | CPC: |
A61K31/42 (EP,IL,KR,US);
A61K9/2886 (EP,IL,KR,US);
A23L33/10 (IL,US);
A23L33/127 (EP,IL);
A61K9/2009 (IL,US);
A61K9/2018 (IL,US);
A61K9/2054 (IL,US);
A61K9/2059 (IL,US);
A61K9/2063 (IL,US);
A61K9/2086 (IL,US);
A61K9/282 (IL,US);
A61K9/2846 (IL,KR,US);
A61K9/2866 (IL,KR,US);
A61K9/485 (IL,US);
A61K9/4858 (IL,US);
A61K9/4866 (IL,US);
A61K9/4891 (EP,IL,KR,US);
A61K9/7023 (KR);
A61K9/7084 (EP);
A61P25/00 (KR);
A61P25/16 (EP,IL,US);
A61P25/18 (EP,IL,US);
A61P25/22 (EP,IL,US);
A61P25/24 (EP,IL,US);
A61P25/28 (EP,IL,US);
A61P31/06 (EP,IL,US);
A23V2002/00 (IL,US);
A23V2200/322 (IL,US)
(-)
|
| Former IPC [2021/29] | A61K9/28, A61K31/42, A61K9/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/29] | Title | German: | FORMULIERUNGEN VON CYCLOSERINVERBINDUNGEN UND IHRE VERWENDUNGEN | [2021/29] | English: | FORMULATIONS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF | [2021/29] | French: | FORMULATIONS DE COMPOSÉS DE CYCLOSÉRINE ET LEURS APPLICATIONS | [2021/29] | Entry into regional phase | 09.04.2021 | National basic fee paid | 09.04.2021 | Search fee paid | 09.04.2021 | Designation fee(s) paid | 09.04.2021 | Examination fee paid | Examination procedure | 09.04.2021 | Examination requested [2021/29] | 05.01.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 03.08.2021 | Renewal fee patent year 03 | 26.07.2022 | Renewal fee patent year 04 | 27.09.2023 | Renewal fee patent year 05 | 26.09.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO2005016319 (UNIV EMORY [US], et al) [X] 1,3,10-12 * example 8 *; | [A]US2005143314 (PATRICK JASON [US], et al) [A] 1-14 * paragraphs [0128] - [0129]; examples 12-13, 16 *; | [A]US2010113453 (MCDEVITT JASON P [US], et al) [A] 1-14 * paragraphs [0011] - [0014] - [ 0018] , [ 0025] ** paragraphs [0032] , [ 0048] , [ 0053] , [ 0060] *; | [XI]WO2017017585 (MOHAN M ALAPATI [IN]) [X] 1,3,5,8-12 * paragraphs [0031] , [ 0044] , [ 0062] - [0065] * * paragraphs [0074] - [0075] - [ 0098] , [ 00113] , [ 00159] * [I] 2,6,7; | [X]WO2017024129 (CONFLUENCE PHARMACEUTICALS LLC [US]) [X] 1,10-14 * page 12, lines 13-14; claims 17-18 * * page 6, paragraph last * * page 5, paragraph last *; | [X]WO2018043850 (UNIV YEUNGNAM RES COOPERATION FOUNDATION [KR]) [X] 1,3,4,11,12 * paragraphs [0057] - [0064]; examples 28-31 * |